Cannabinoids for medical use: A systematic review and meta-analysis

JAMA - Journal of the American Medical Association

Volumn 313, Issue 24, 2015, Pages 2456-2473

  Whiting, Penny F ^a,b,c   Wolff, Robert F ^c   Deshpande, Sohan ^c   Di Nisio, Marcello ^d,e   Duffy, Steven ^c   Hernandez, Adrian V ^f,g   Keurentjes, J Christiaan ^h   Lang, Shona ^c   Misso, Kate ^c   Ryder, Steve ^c   Schmidlkofer, Simone ⁱ   Westwood, Marie ^c   Kleijnen, Jos ^c,j  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^c KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

^d UNIVERSITY OF CHIETI   (Italy)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UNIVERSIDAD PERUANA DE CIENCIAS APLICADAS   (Peru)

^g LERNER RESEARCH INSTITUTE   (United States)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ Institut für Epidemiologie und Kongenitale Erkrankungen   (Germany)

^j MAASTRICHT UNIVERSITY   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALIZAPRIDE; AMITRIPTYLINE; CANNABINOID; CANNABINOID DERIVATIVE; CHLORPROMAZINE; DIHYDROCODEINE; DOMPERIDONE; DRONABINOL; ECP 00 2 A; GABAPENTIN; HYDROXYZINE; LEVONANTRADOL; MEDICAL CANNABIS; MEGESTROL ACETATE; METOCLOPRAMIDE; NABILONE; NABIXIMOLS; ONDANSETRON; PLACEBO; PROCHLORPERAZINE; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANXIETY DISORDER; APPETITE DISORDER; ASTHENIA; BALANCE DISORDER; CANCER PAIN; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC PAIN; CONFUSION; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; EUPHORIA; EVIDENCE BASED MEDICINE; FATIGUE; GILLES DE LA TOURETTE SYNDROME; GLAUCOMA; HALLUCINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; META ANALYSIS; MOTOR DYSFUNCTION; NAUSEA; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PARANOIA; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SLEEP DISORDER; SOCIAL PHOBIA; SOMNOLENCE; SPASTICITY; SYSTEMATIC REVIEW; VOMITING; WEIGHT GAIN; XEROSTOMIA; ANOREXIA; MENTAL DISORDERS; MUSCLE SPASTICITY; TOURETTE SYNDROME;

ANOREXIA; CANNABINOIDS; CHRONIC PAIN; GLAUCOMA; HUMANS; MEDICAL MARIJUANA; MENTAL DISORDERS; MUSCLE SPASTICITY; NAUSEA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOURETTE SYNDROME;

EID: 84937597764     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.6358     Document Type: Review

References (197)

1. Small E, Cronquist A. A practical and natural taxonomy for cannabis. Taxon. 1976;25(4):405-435. doi:10.2307/1220524.
2. Poznyak V. SY14-1 global epidemiology of cannabis use and implications for public health. Alcohol Alcohol. 2014;49(suppl 1):i14. doi:10.1093/alcalc/agu052.58 i.
3. United Nations. Single Convention on Narcotic Drugs, 1961. New York, NY: United Nations; 1962.
4. Hazekamp A, Ware MA, Müller-Vahl KR, Abrams D, Grotenhermen F. The medicinal use of cannabis and cannabinoids - an international cross-sectional survey on administration forms. J Psychoactive Drugs. 2013;45(3):199-210.
5. Hazekamp A, Heerdink ER. The prevalence and incidence of medicinal cannabis on prescription in the Netherlands. Eur J Clin Pharmacol. 2013;69(8):1575-1580.
6. Office of National Drug Control Policy. Marijuana Resource Center: State Laws Related to Marijuana. https://www.whitehouse.gov/ondcp/state-laws-related-to-marijuana. Accessed May 18, 2015.
7. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration website. http://handbook.cochrane.org/. Accessed March 23, 2011.
8. Centre for Reviews and Dissemination. Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care (Internet). York, England: University of York; 2009. https://www.york.ac.uk/media/crd/Systematic-Reviews.pdf. Accessed March 23, 2011.
9. Canadian Agency for Drugs and Technologies in Health. CADTH Peer Review Checklist for Search Strategies (Internet). Ottawa, Canada: CADTH; 2013. https://www.cadth.ca/resources/finding-evidence/cadth-peer-review-checklist-search-strategies. Accessed March 17, 2014.
10. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2):206-207.
11. Higgins JP, Altman DG, Gøtzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.1986;7(3):177-188.
13. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
14. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. rating the quality of evidence - study limitations (risk of bias). J Clin Epidemiol. 2011;64(4):407-415.
15. Broder LE, Lean NL, Hilsenbeck SG. A randomized blinded clinical trial comparing delta-9-tetrahydrocannabinol (THC) and hydroxizine (HZ) as antiemetics (AE) for cancer chemotherapy (CT). Proc Am Assoc Cancer Res. 1982;23:514.
16. Long A, Mioduszewski J, Natale R. A randomized double-blind cross-over comparison of the antiemetic activity of levonantradol and prochlorperazine. Proc Am Soc Clin Oncol. 1982;1:C-220.
17. nd Conference on Cannabinoids in Medicine; September 12-13, 2003; Cologne, Germany.
18. Prasad B, Radulovacki MG, Carley DW. Randomized placebo controlled trial of dronabinol in obstructive sleep apnea. Paper presented at: American Thoracic Society International Conference, ATS 2011; May 13-18, 2011; Denver, CO. Am J Respir Crit Care Med. 2011;183(1):A2720.
19. GW Pharmaceuticals Ltd. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT01606202. Accessed April 7, 2014.
20. Center for Medicinal Cannabis Research. Efficacy of inhaled cannabis in diabetic painful peripheral neuropathy. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00781001. Accessed April 7, 2014.
21. Stanley Medical Research Institute, Coordinating Centre for Clinical Trials Cologne. University of Cologne. A clinical trial on the antipsychotic properties of cannabidiol. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00309413. Accessed April 7, 2014.
22. GW Pharma Ltd. A double blind, randomised, placebo controlled, parallel group study of Sativex in the treatment of subjects with pain due to diabetic neuropathy. EU Clinical Trials Register. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract-number:2004-002530-20. Accessed August 4, 2014.
23. GW Pharmaceuticals Ltd. A study to evaluate the effects of cannabis based medicine in patients with pain of neurological origin. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT01606176 Accessed April 7, 2014.
24. Duran M, Pérez E, Abanades S, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol. 2010;70(5):656-663.
25. Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23(3):533-543.
26. Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage. 1991;6(6):352-359.
27. McCabe M, Smith FP, Macdonald JS, Woolley PV, Goldberg D, Schein PS. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs. 1988;6(3):243-246.
28. Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial.Pediatrics. 1987;79(6):946-952.
29. Pomeroy M, Fennelly JJ, Towers M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol. 1986;17(3):285-288.
30. Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Child. 1986;61(5):502-505.
31. Niederle N, Schütte J, Schmidt CG. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr. 1986;64(8):362-365.
32. Niiranen A, Mattson K. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol. 1985;8(4):336-340.
33. Heim ME, Queisser W, Altenburg HP. Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy. Cancer Chemother Pharmacol. 1984;13(2):123-125.
34. Hutcheon AW, Palmer JB, Soukop M, et al. A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur J Cancer Clin Oncol. 1983;19(8):1087-1090.
35. George M, Pejovic MH, Thuaire M, Kramar A, Wolff JP. [Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin]. Biomed Pharmacother. 1983;37(1):24-27.
36. Jones SE, Durant JR, Greco FA, Robertone A. A multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting. Cancer Treat Rev. 1982;9(suppl B):45-48.
37. Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE. Double-blind, randomized, crossover trial of nabilone vs placebo in cancer chemotherapy. Cancer Treat Rev. 1982;9(suppl B):39-44.
38. Johansson R, Kilkku P, Groenroos M. A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev. 1982;9(suppl B):25-33.
39. Orr LE, McKernan JF. Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. J Clin Pharmacol. 1981;21(8-9 suppl):76S-80S.
40. Einhorn LH, Nagy C, Furnas B, Williams SD. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol. 1981;21(8-9 suppl):64S-69S.
41. Orr LE, McKernan JF, Bloome B. Antiemetic effect of tetrahydrocannabinol: compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med. 1980;140(11):1431-1433.
42. Steele N, Gralla RJ, Braun DW Jr, Young CW. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep. 1980;64(2-3):219-224.
43. Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med. 1980;302(3):135-138.
44. Frytak S, Moertel CG, O'Fallon JR, et al. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy: a comparison with prochlorperazine and a placebo. Ann Intern Med. 1979;91(6):825-830.
45. Ahmedzai S, Carlyle DL, Calder IT, Moran F. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer. 1983;48(5):657-663.
46. Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer. 1982;50(4):636-645.
47. Sheidler VR, Ettinger DS, Diasio RB, Enterline JP, Brown MD. Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine. J Clin Pharmacol. 1984;24(4):155-159.
48. Harden-Harrison MM, Munsell MF, Fisch MJ, et al. Dronabinol for the prevention of nausea from cyclophosphamide and/or adriamycin. Paper presented at: International MASCC/ISOO Symposium: Supportive Care in Cancer; June 28-30, 2012; New York, NY. Support Care Cancer. 2012;20:S209-S210.
49. Grunberg SM, Munsell MF, Morrow PKH, et al. Randomized double-blind evaluation of dronabinol for the prevention of chemotherapy-induced nausea. Paper presented at: Annual Meeting of the American Society of Clinical Oncology (ASCO); 1-5 Jun 2012; Chicago, IL. J Clin Oncol. 2012;30(15)(suppl 1):9061.
50. Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in combination are better than either single agent alone for treatment of chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol. 1989;8:326.
51. Levitt M. Nabilone vs placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treat Rev. 1982;9(suppl B):49-53.
52. Chan HS, MacLeod SM, Correia JA. Nabilone vs prochlorperazine for control of cancer chemotherapy-induced emesis in children. Proc Am Soc Clin Oncol. 1984;3:108.
53. Solvay Pharmaceuticals. Dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00642512 Accessed April 7, 2014.
54. Frytak S, Moertel CG, Ofallon JR. Comparison of delta-9-tetrahydrocannabinol (THC), prochlorperazine (PCP) and placebo as anti-emetics for cancer-chemotherapy. Proc Am Assoc Cancer Res. 1979;20:391.
55. Jhangiani H, Vredenburgh JJ, Barbato L, et al. Dronabinol or ondansetron alone and combined for delayed chemotherapy-induced nausea and vomiting (CINV). Blood. 2005;106(11, part 2):477B.
56. McCabe M, Smith FP, Goldberg D, et al. Comparative trial of oral 9 tetrahydrocannabinol and prochlorperazine for cancer chemotherapy related nausea and vomiting. Proc Am Assoc Cancer Res and Am Soc Clin Oncol. 1981;22:416.
57. Herman TS, Einhorn LH, Jones SE, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med. 1979;300(23):1295-1297.
58. Melhem-Bertrandt AI, Munsell MF, Fisch MJ, et al. A randomized, double-blind, placebo-controlled trial of palonosetron plus dexamethasone with or without dronabinol for the prevention of chemotherapy-induced nausea and vomiting after moderately emetogenic chemotherapy [Unpublished manuscript]. 2014:1-23.
59. Abrams DI, Hilton JF, Leiser RJ, et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med.2003;139(4):258-266.
60. Timpone JG, Wright DJ, Li N, et al; Division of AIDS Treatment Research Initiative. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome: the DATRI 004 Study Group. AIDS Res Hum Retroviruses. 1997;13(4):305-315.
61. Struwe M, Kaempfer SH, Geiger CJ, et al. Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother. 1993;27(7-8):827-831.
62. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995;10(2):89-97.
63. Ware M, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Paper presented at: Canadian Rheumatology Association Meeting; February 18-21, 2009; Kananaskis, AB: Canada. Abstract 149 J Rheumatol. 2009;36(11):2607.
64. Ware MA, Fitzcharles M-A, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110(2):604-610.
65. Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013;260(4):984-997.
66. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14(2):136-148.
67. Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438-449.
68. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 2010;182(14):E694-E701.
69. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39(2):167-179.
70. Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care. 2010;33(1):128-130.
71. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34(3):672-680.
72. Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9(6):506-521.
73. Narang S, Gibson D, Wasan AD, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008;9(3):254-264.
74. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9(2):164-173.
75. Frank B, Serpell MG, Hughes J, Matthews JNS, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ. 2008;336(7637):199-201.
76. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain.2007;133(1-3):210-220.
77. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515-521.
78. Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Pölz W. [Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain - a randomized controlled trial]. Wien Klin Wochenschr. 2006;118(11-12):327-335.
79. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):50-52.
80. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819.
81. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112(3):299-306.
82. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? randomised double blind placebo controlled crossover trial. BMJ. 2004;329(7460):253.
83. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA. 2003;290(13):1757-1762.
84. Noyes R Jr, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol. 1975;15(2-3):139-143.
85. Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage. 2014;47(1):166-173.
86. nd Annual Scientific Meeting of the American Pain Society; May 9-11, 2013; New Orleans: LA. J Pain. 2013;14(4)(suppl 1):S62 doi:10.1016/j.jpain.2013.01.587.
87. Berman J, Bosworth T, Guy G, Stott C; Sativex Spinal Cord Injury Study Group. Sativex in the treatment of central neuropathic pain due to spinal cord injury: a randomised controlled study. Paper presented at: British Pain Society Annual Scientific Meeting; April 2007; Glasgow: United Kingdom.
88. Serpell M, Ratcliffe S, Hovorka J, et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014;18(7):999-1012.
89. Fitzcharles MA, Shir Y, Joseph L, Ware MA. The effects of nabilone on insomnia in fibromyalgia: results of a randomized controlled trial. Paper presented at: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP 09); November 6-11, 2009; Atlanta: GA. Arthritis Rheum. 2009;60:1429.
90. McGill University Health Center. Nabilone versus amitriptyline in improving quality of sleep in patients with fibromyalgia. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00381199 Accessed April 7, 2014.
91. GW Pharmaceuticals Ltd. Sativex versus placebo when added to existing treatment for central neuropathic pain in MS. http://ClinicalTrials.gov/show/NCT00391079 Accessed April 7, 2014.
92. Svendsen KB, Jensen TS, Bach FW. [Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis-secondary publication]. Ugeskr Laeger. 2005;167(25-31):2772-2774.
93. Salim K, Schneider U, Burstein S, Hoy L, Karst M. Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology. 2005;48(8):1164-1171.
94. th International Conference on Early Psychosis: From Neurobiology to Public Policy; October 11-13, 2012; San Francisco: CA. Eur Spine J. 2012;21(11):2366 doi:10.1007/s00586-012-2522-6.
95. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ. A multi-centre, double-blind, randomized, controlled trial of oro-mucosal cannabis based medicine in the treatment of neuropathic pain characterized by allodynia. Neurology. 2005;64(suppl 1):A374.
96. Issa MA, Narang S, Jamison RN, et al. The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain. Clin J Pain. 2014;30(6):472-478.
97. rd Conference on Cannabinoids in Medicine; September 9-10, 2005; Leiden, the Netherlands.
98. Young CA, Rog DJ. Randomised controlled trial of cannabis based medicinal extracts (CBME) in central neuropathic pain due to multiple sclerosis. Paper presented at: IV Congress of the European Federation of IASP Chapters (EFIC); September 2-6, 2003; Prague, Czech Republic.
99. Berman J, Lee J, Cooper M, et al. Efficacy of two cannabis-based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Paper presented at: Pain Society Annual Meeting; April 1-4, 2003; Glasgow, United Kingdom. Anaesthesia. 2003;58(9):938 doi:10.1046/j.1365-2044.2003.03408-3.x.
100. Center for Medicinal Cannabis Research. Effects of smoked marijuana on neuropathic pain. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00254761. Accessed April 7, 2014.
101. Center for Medicinal Cannabis Research. Medicinal cannabis for painful HIV neuropathy. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00255580. Accessed April 7, 2014.
102. University of California Davis. Center for Medicinal Cannabis Research, VA Northern California Health Care System. Effects of vaporized marijuana on neuropathic pain. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT01037088. Accessed April 7, 2014.
103. Center for Medicinal Cannabis Research. Marijuana for HIV-related peripheral neuropathy. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00046722. Accessed April 7, 2014.
104. GW Pharmaceuticals Ltd. A study of Sativex® for pain relief in patients with advanced malignancy. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00530764. Accessed April 7, 2014.
105. GW Pharmaceuticals Ltd. A study of sativex® for pain relief in patients with advanced malignancy. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00674609. Accessed April 7, 2014.
106. GW Pharmaceuticals Ltd. A study of sativex® for relief of peripheral neuropathic pain associated with allodynia. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00711880. Accessed April 7, 2014.
107. GW Pharmaceuticals Ltd. A study of sativex in the treatment of central neuropathic pain due to multiple sclerosis. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT01604265. Accessed April 7, 2014.
108. GW Pharmaceuticals Ltd. A study of sativex® for pain relief due to diabetic neuropathy. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00710424. Accessed April 7, 2014.
109. GW Pharmaceuticals Ltd. A study of Sativex® for pain relief of peripheral neuropathic pain, associated with allodynia. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00710554. Accessed April 7, 2014.
110. Mary Lynch, Capital District Health Authority Canada. Sativex for treatment of chemotherapy induced neuropathic pain. .ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00872144. Accessed April 7, 2014.
111. Brigham and Women's Hospital; Solvay Pharmaceuticals. Study to evaluate the efficacy of dronabinol (Marinol) as add-on therapy for patients on opioids for chronic pain. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00153192. Accessed April 7, 2014.
112. Winnipeg Regional Health Authority; Valeant Canada Limited. A trial assessing the effect of nabilone on pain and quality of life in patients with fibromyalgia. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00272207. Accessed April 7, 2014.
113. GW Pharma Ltd. A double blind, randomised, placebo controlled parallel group study of cannabis based medicine extract (CBME), in the treatment of peripheral neuropathic pain characterised by allodynia. metaRegister of Controlled Trials. http://www.controlled-trials.com/ISRCTN38250575. Accessed April 7, 2014.
114. Montreal General Hospital. Pilot study of smoked cannabis for chronic neuropathic pain. metaRegister of Controlled Trials (mRCT), http://www.controlled-trials.com/ISRCTN68314063. Accessed April 7, 2014.
115. GW Pharma Ltd. A double blind, randomised, placebo controlled, parallel group study of Sativex, in the treatment of subjects with peripheral neuropathic pain associated with allodynia. EU Clinical Trials Register. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract-number:2004-002531-32. Accessed April 8, 2014.
116. Cambridge Laboratories Ltd. A randomised, crossover, double blind comparison of the analgesic effect and patient tolerability of nabilone and dihydrocodeine in chronic neuropathic pain. metaRegister of Controlled Trials. http://isrctn.org/ISRCTN15330757. Accessed April 7, 2014.
117. Selvarajah D, Gandhi RA, Witte D, Bowler H, Emery C, Tesfaye S. Treatment of painful diabetic neuropathy with Sativex (a cannabis based medicinal product)-results of a randomised placebo controlled trial. Diabetologia. 2006;49 (suppl 1):671-672 doi:10.1007/s00125-006-0358-5.
118. Rog DJ, Nurmikko T, Young C, Sarantis NS. Randomized controlled trial of sativex, a cannabis based medicine (CBM), in central neuropathic pain due to multiple sclerosis, followed by an open-label extension. Neurology. 2006;66(5):A31.
119. Ventegodt S, Merrick J. Psychoactive drugs and quality of life. ScientificWorldJournal. 2003;3:694-706.
120. Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of inhaled cannabis on painful diabetic neuropathy. J Pain. 2015;pii:S1526-5900(1515)00601-X.
121. Turcotte D, Doupe M, Torabi M, et al. Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. Pain Med. 2015;16(1):149-159.
122. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76(12):1664-1669.
123. Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83(11):1125-1132.
124. Corey-Bloom J, Wolfson T, Gamst A, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ. 2012;184(10):1143-1150.
125. Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32(5):451-459.
126. Pooyania S, Ethans K, Szturm T, Casey A, Perry D. A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Arch Phys Med Rehabil. 2010;91(5):703-707.
127. Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290-296.
128. Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(6):636-641.
129. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? a double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434-441.
130. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004;10(4):417-424.
131. Zajicek J, Fox P, Sanders H, et al; UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9395):1517-1526.
132. Killestein J, Hoogervorst ELJ, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 2002;58(9):1404-1407.
133. th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 10-13, 2012; Lyon: France. Mult Scler. 2012;18(4 suppl 1):247.
134. th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; September 9-12, 2009; Dusseldorf: Germany. Mult Scler. 2009;15(9)(suppl S):S274 doi:10.1177/1352458509107025.
135. Killestein J, Hoogervorst ELJ, Kalkers NF, et al. The effects of orally administred cannabinoids in multiple sclerosis patients: a pilot study. Mult Scler. 2000;6(1 suppl 1):S28 doi:10.1177/135245850000600101.
136. th Conference on Cannabinoids in Medicine; October 2-3, 2009; Cologne, Germany.
137. nd Congress of the ECTRIMS; September 27-30, 2006; Madrid, Spain.
138. rd Conference on Cannabinoids in Medicine; September 9-10, 2005; Leiden, the Netherlands.
139. Center for Medicinal Cannabis Research. Short-term effects of medicinal cannabis therapy on spasticity in multiple sclerosis. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00248378. Accessed April 7, 2014.
140. Institut fur Klinische Forschung Germany; Weleda AG. Multiple Sclerosis and Extract of Cannabis (MUSEC) study. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00552604. Accessed April 7, 2014.
141. GW Pharmaceuticals Ltd. A study of Sativex® for relief of spasticity in subjects with multiple sclerosis. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00711646. Accessed April 7, 2014.
142. GW Pharmaceuticals Ltd. A study to evaluate the efficacy of Sativex in relieving symptoms of spasticity due to multiple sclerosis. ClinicalTrials.gov.http://ClinicalTrials.gov/show/NCT01599234. Accessed April 7, 2014.
143. GW Pharmaceuticals Ltd. An investigation of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in multiple sclerosis patients. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT01610700. Accessed April 7, 2014.
144. University of Manitoba, Valeant Canada Limited. Randomized double blind cross over study for nabilone in spasticity in spinal cord injury persons. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00623376. Accessed April 7, 2014.
145. Medical Research Council (MRC). A multiple randomised controlled trial of cannabinoids on spasticity in multiple sclerosis (MS). metaRegister of Controlled Trials. http://www.controlled-trials.com/ISRCTN39371386. Accessed April 7, 2014.
146. Gesellschaft fuer klinische Forschung e.V. Multiple Sclerosis and Extract of Cannabis (MUSEC): a randomised, double-blind, placebo-controlled phase III trial to determine the efficacy and safety of a standardised oral extract of cannabis sativa for the symptomatic relief of muscle stiffness and pain in multiple sclerosis. EU Clinical Trials Register. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract-number:2005-005263-29. Accessed April 8, 2014.
147. Corey-Bloom J, Wolfson TJ, Anthony GC, Bentley H, Gouaux B. Short-term effects off medicinal cannabis on spasticity in multiple sclerosis. Neurology. 2008;70(11)(suppl 1):A86-A87.
148. Leocani L, Nuara A, Houdayer E, et al. Effect of THC-CBD oromucosal spray (Sativex) on measures of spasticity in multiple sclerosis: a double-blind, placebo-controlled, crossover study. Paper presented at: Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting; September 10-13, 2014; Boston, MA. Mult Scler. 2014;20(1 suppl 1):498 doi:10.1177/1352458514547846.
149. Van Amerongen G, Beumer T, Killestein J, Groeneveld GJ. Individualized dosing of a novel oral DELTA9-THC formulation improves subjective spasticity and pain in patients with progressive multiple sclerosis. Paper presented at Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting; September 10-13, 2014; Boston, MA. Mult Scler. 2014;20(1)(suppl 1):478-479 doi:10.1177/1352458514547846.
150. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-1226.
151. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94.
152. st ECNP Congress; August 30, 2008; Barcelona, Spain. Eur Neuropsychopharmacol. 2008;18(S4):S171 doi:10.1016/S0924-977X(08)70156-1.
153. th European Psychiatric Association, EPA Congress; January 24-28, 2009; Lisbon, Portugal. Eur Psychiatry. 2009;24(supp 1):S207 doi:10.1016/S0924-9338(09)70440-7.
154. University of Cologne. Evaluation of the antipsychotic efficacy of cannabidiol in acute schizophrenic psychosis. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00628290. Accessed April 7, 2014.
155. th International Conference on Early Psychosis: From Neurobiology to Public Policy; October 11-13, 2012; San Francisco, CA. Early Interv Psychiatry. 2012;6(suppl 1):7 doi:10.1111/j.1751-7893.2012.00392.x.
156. th International Congress on Schizophrenia Research, ICOSR; April 2-6, 2011; Colorado Springs, CO. Schizophr Bull. 2011;37(suppl 1):313 doi:10.1093/schbul/sbq173.
157. th Annual Conference of the American College of Neuropsychopharmacology, ACNP 2010; December 5-9, 2010; Miami Beach, FL. Neuropsychopharmacology. 2010;35(suppl 1):S280 doi:10.1038/npp.2010.217.
158. th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry; May 3-5, 2012; Philadelphia, PA. Biol Psychiatry. 2012;78(8)(suppl 1):63S.
159. Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 2006;15(5):349-353.
160. Müller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U. Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology. 2003;28(2):384-388.
161. Müller-Vahl KR, Schneider U, Prevedel H, et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry. 2003;64(4):459-465.
162. Müller-Vahl KR, Koblenz A, Jöbges M, Kolbe H, Emrich HM, Schneider U. Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. Pharmacopsychiatry. 2001;34(1):19-24.
163. Müller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry.2002;35(2):57-61.
164. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. MeDRA (Medical Dictionary for Regulatory Activities). http://www.meddra.org/. Accessed September 2, 2014.
165. McGowan J, Sampson M, Lefebvre C. An evidence based checklist for the peer review of electronic search strategies (PRESS EBC). Evid Based Libr Inf Pract. 2010;5(1):1-6. http://ejournals.library.ualberta.ca/index.php/EBLIP/article/view/7402. Accessed Month, date, year.
166. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol. 2002;31(1):140-149.
167. Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol. 2009;9:59.
168. Sevilla Guerra S. Are cannabinoids more effective than placebo in decreasing MS-related bladder dysfunction? Br J Neurosci Nurs. 2012;8(2):71-78 doi:10.12968/bjnn.2012.8.2.71.
169. Shakespeare D, Boggild M, Young CA. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev. 2003;(4):CD001332.
170. Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler. 2010;16(6):707-714.
171. Brook JS, Lee JY, Finch SJ, Brown EN. Course of comorbidity of tobacco and marijuana use: psychosocial risk factors. Nicotine Tob Res.2010;12(5):474-482.
172. Machado Rocha FC, Stéfano SC, De Cássia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl). 2008;17(5):431-443.
173. Phillips RS, Gopaul S, Gibson F, et al Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst Rev. 2010;(9):CD007786.
174. Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323(7303):16-21.
175. van den Elsen GAH, Ahmed AIA, Lammers M, et al. Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing Res Rev. 2014;14(1):56-64.
176. Burns TL, Ineck JR. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother. 2006;40(2):251-260.
177. Campbell FA, Tramèr MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? a qualitative systematic review. BMJ. 2001;323(7303):13-16.
178. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids as Co-Analgesics: Review of Clinical Effectiveness. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health;2010.
179. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids for the Management of Neuropathic Pain: Review of Clinical Effectiveness. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health);2010.
180. Davis MP. Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs. 2008;17(1):85-95.
181. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007;23(1):17-24.
182. Jawahar R, Oh U, Yang S, Lapane KL. A systematic review of pharmacological pain management in multiple sclerosis. Drugs. 2013;73(15):1711-1722.
183. nd Mexican-Canadian Congress of Rheumatology; February 10-15, 2011; Cancun, Mexico.JRheumatol. 2011;38(6):1171 doi:10.3899/jrheum.110506.
184. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72(5):735-744.
185. Martín-Sánchez E, Furukawa TA, Taylor J, Martin JL. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med. 2009;10(8):1353-1368.
186. Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One.2010;5(12):e14433.
187. Pittler MH, Ernst E. Complementary therapies for neuropathic and neuralgic pain: systematic review. Clin J Pain. 2008;24(8):731-733.
188. Richards BL, Whittle SL, Buchbinder R. Neuromodulators for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2012;(1):CD008921.
189. Boychuk DG, Goddard G, Mauro G, Orellana MF. The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review. J Oral Facial Pain Headache. 2015;29(1):7-14.
190. Parsai S, Herman R, Johnson S. Systematic literature review of randomized controlled trials to evaluate the efficacy of medical marijuana for analgesia. Paper presented at: Annual Meeting of the American College of Clinical Pharmacy; October 12-15, 2014; Austin, TX. Pharmacotherapy. 2014;34(10):e287 doi:10.1002/phar.1497.
191. Lynch ME, Ware MA. Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials [published online March 22, 2015]. J Neuroimmune Pharmacol doi.org/10.1007/s11481-015-9600-6.
192. Rathbone J, Variend H, Mehta H. Cannabis and schizophrenia. Cochrane Database Syst Rev. 2008;(3):CD004837.
193. th European College of Neuropsychopharmacology, ECNP Congress; October 5-9, 2013; Barcelona, Spain. Eur Neuropsychopharmacol. 2013;23:S216-S217 doi:10.1016/S0924-977X(13)70334-1.
194. Zammit S, Moore THM, Lingford-Hughes A, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry. 2008;193(5):357-363.
195. Curtis A, Clarke CE, Rickards HE. Cannabinoids for Tourette's syndrome. Cochrane Database Syst Rev. 2009;CD0065652009(4):CD006565.
196. Waldon K, Hill J, Termine C, Balottin U, Cavanna AE. Trials of pharmacological interventions for Tourette syndrome: a systematic review. Behav Neurol. 2013;26(4):265-273.
197. Boers M. Updated Consolidated Standards of Reporting Trials (CONSORT): it just gets better. J Clin Epidemiol. 2010;63(8):813-814.